Looks like you clickedhttps://www.urotoday.com/conference-highlights/asco-gu-2023/asco-gu-2023-prostate-cancer/142449-asco-gu-2023-efficacy-and-safety-of-darolutamide-in-combination-with-adt-and-docetaxel-by-disease-volume-and-disease-risk-in-the-phase-3-arasens-study.html?utm_source=newsletter_11337&utm_medium=email&utm_campaign=parp-inhibitors-in-mcrpc-talapro-2-and-triton3-and-new-targets-new-drugs-new-victories-in-advanced-prostate-cancer-asco-gu-2023
If you do not want to visit that page, you can close this browser tab.
